Oklahoma Clinical Care Guidelines
Stimulant Use for Members Under the Age of 5

Oklahoma Health Care Authority

- ❑ **The OHCA defines which stimulants are on formulary and which tier they are in via the ADHD Tier Chart listed here: https://oklahoma.gov/ohca/providers/types/pharmacy/prior-authorization/2024/central-nervous-system-behavioral-health.html This information could be updated once weekly and is communicated electronically to OCH via a drug extract file.**

Introduction

- ❑ **Most stimulants used to treat ADHD are considered off-label for children younger than 6 years. The Preschool ADHD Treatment Study (PATS) was a complex multi–site, randomized trial, designed to evaluate the efficacy and safety of immediate–release methylphenidate in the preschool population. A follow up study was done on this population 9 years later. Results showed that preschool children are more likely to have side effects to stimulants and stimulants are not as effective in young children.**
- ❑ **First line treatment for ADHD in young children is behavioral therapy through parent training management training, pharmacotherapy is typically reserved for severe cases.**
- ❑ **Due to the sparsity of literature, these clinical guidelines provide guidance on reviewing stimulant prior authorizations for medical necessity for children under the age of 5.**

FDA Approved Indication

- ❑ **Adderall has been FDA approved for ages 3 and up; however, current guidelines do not recommend Adderall use in children under 6 due to insufficient evident. Studies were conducted on children ages 5 and up.**
- ❑ **Methylphenidate is FDA-approved for treating attention deficit hyperactivity disorder (ADHD) in children ages 6 and up. Methylphenidate has been researched in the preschool population in several studies including the Preschool ADHD Treatment Studies. AAP considers immediate release products first-line agent in children aged 3 to 5 if pharmacological treatment is deemed necessary.**

Initial Approval Criteria

Stimulant initiation for children under 5 years of age is considered medically necessary when the following criteria are met:

- ❑ **Child diagnosed, per current Diagnostic and Statistical Manual criteria, with one of the following disorders:**

- Attention Deficit Hyperactivity Disorder, Inattentive Type
- Attention Deficit Hyperactivity Disorder, Hyperactive Type
- Attention Deficit Hyperactivity Disorder, Combined Type

- ❑ **Provider must submit documentation (including office chart notes and lab results) of the below items:**
  - A child psychiatry evaluation by a child psychiatrist OR consultation with a child psychiatrist with a recommendation of a stimulant trial.
  - Evaluation of psychosocial issues.
  - Evaluation of cardiac health.
  - Consideration of co-morbid developmental language disorder, Specific Learning Disorder, hearing loss or Autism Spectrum Disorder (ASD).
  - Vitals signs including weight, height, BMI, pulse, and blood pressure.
  - ADHD screening tool results (e.g., Vanderbilt ADHD Rating Scale) from 2 sources (e.g., caregiver and childcare worker).
  - Parent Management Training or other Behavioral intervention for at least 12 weeks.
  - Documented continued impairment after non-medication intervention.
- ❑ **The requested dose does NOT exceed the dosing guidelines below.**
  - **Initial Dosing**
    - Methylphenidate IR 5mg po q AM
    - Amphetamine Salts/Dextroamphetamine IR 2.5 mg po q AM

CONTINUATION THERAPY, DOSE CHANGES, FORMULATION CHANGES

Stimulant continuation, dose changes or formulation changes for children under 5 years of age is medically necessary when the following criteria are met:

- ❑ **Child diagnosed, per current Diagnostic and Statistical Manual criteria, with one of the following disorders:**
  - Attention Deficit Hyperactivity Disorder, Inattentive Type
  - Attention Deficit Hyperactivity Disorder, Hyperactive Type
  - Attention Deficit Hyperactivity Disorder, Combined Type
- ❑ **Provider must submit documentation (including office chart notes and lab results) of the below items:**
  - ADHD Follow Up visit/s by a physician which include:
    - Current ADHD symptoms
    - Side effects and benefits of ADHD medication and reasons for any changes.
    - Vitals signs including weight, height, BMI, pulse, and blood pressure.
    - ADHD follow up screening tool such as the follow up Vanderbilt from 2 sources.
    - Documentation of psychosocial support and/or continued therapy.
- ❑ **Initial dose has been tried for at least 4 weeks unless there is documentation showing clinical justification (e.g., side effects).**
- ❑ **The requested dose does NOT exceed the dosing guidelines below.**
  - Dosing
    - Methylphenidate dose does not exceed 1mg/kg/day.
    - Dextroamphetamine or mixed amphetamine salts dose does not exceed 0.5 mg/kg/day.
- ❑ **If this is a formulation change request:**
  - A minimum trial of up to 20 mg of methylphenidate daily before transitioning to a long acting/extended release of methylphenidate.

- A minimum trial of up to 10 mg of dextroamphetamine or mixed amphetamine salts daily before transitioning to a long acting/extended release of dextroamphetamine or mixed amphetamine salts.

LENGTH OF APPROVAL

6 months

REFERENCES

1. Vitiello B, Lazzaretto D, Yershova K, Abikoff H, Paykina N, McCracken JT, McGough JJ, Kollins SH, Greenhill LL, Wigal S, Wigal T, Riddle MA. Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up. J Am Acad Child Adolesc Psychiatry. 2015 Jul;54(7):550-6. doi: 10.1016/j.jaac.2015.04.004. Epub 2015 Apr 27. PMID: 26088659; PMCID: PMC4475273.
2. Wigal, T., Greenhill, L., Chuang, S., McGough, J., Vitiello, B., Skrobala, A., Swanson, J. et al. (2006). Safety and Tolerability of Methylphenidate in Preschool Children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45(11), 1294–1303.
3. Verghese C, Abdijadid S. Methylphenidate. 2023 Jan 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29494058.
4. Cortese, S. et al. (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry, 5:727–738. 2.
5. Gleason, M. Egger, H., Emslie, G., Greenhill, L., et al. (2007) Psychopharmacological treatment for very young children: Contexts and guidelines. Journal of the American Academy of Child & Adolescent Psychiatry, 46:1532–1572.
6. Greenhill, L., et al. (2006) Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 45(11):1284–1293.
7. Halperin J., Marks, D. (2019) Practitioner review: Assessment and treatment of preschool children with attention-deficit/hyperactivity disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 60(9):930–943.
8. Tandon, M. Pergjika, A. (2017) Attention deficit hyperactivity disorder in preschool-age children. Child and Adolescent Psychiatric Clinics of North America, 26:523–538. 6. Vitiello, B. et al. (2015) Pharmacotherapy of the preschool ADHD treatment study (PATS) children growing up. Journal of the American Academy of Child & Adolescent Psychiatry, 54:550–556.
9. Florida Medicaid Drug Therapy Management Program for Behavioral Health. Principles of Practice Regarding the Use of Psychotherapeutic Medication in children Under 6. http://www.medicaidmentalhealth.org/; http://www.medicaidmentalhealth.org/assets/file/Guidelines/POP_ASD&ID_Under%206.pdf.
10. Drug Facts and Comparisons [online]. 2024. Available from Wolters Kluwer Health, Inc. Accessed April 11, 2024.